ArticleEmerging infectious diseases2018
Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010-2015.
Article in Emerging infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- The impact of pneumococcal conjugate vaccines on disease epidemiology, serotype distribution, and antimicrobial resistance in children. A 25-year observational study in Athens, Greece (1996-2021).Human vaccines & immunotherapeutics · 2026Observational
- Metabolic rewiring at the pyruvate node contributes to severe pneumonia and attenuation of T cell responses in serotype 3 Streptococcus pneumoniae infection.Respiratory research · 2026Article
- Metabolic Rewiring at the Pyruvate Node Drives Severe Pneumonia and T-Cell Suppression in Serotype 3bioRxiv : the preprint server for biology · 2026Article
- The resilience of vaccine serotypes in adult invasive pneumococcal disease in Portugal, 2018-2023.Scientific reports · 2025Article
- Bacterial Acute Otitis Media Complicated with Otorrhea in a Children's Hospital in the Era of Pneumococcal Conjugate Vaccines.Pathogens (Basel, Switzerland) · 2025Article
- Modelling the Epidemiological Impact of Different Adult Pneumococcal Vaccination Strategies in the United Kingdom.Infectious diseases and therapy · 2025Article
- Use of Polymerase Chain Reaction to Characterize the Etiology of Culture-Negative Empyema and Parapneumonic Effusion Among Alaska Native Children-2018-2023.Journal of the Pediatric Infectious Diseases Society · 2025Article
- Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012-2024.Human vaccines & immunotherapeutics · 2024Review
- Serotype 3 Streptococcus pneumoniae Escapes the Immune Responses Induced by PCV13 in Mice With High Susceptibility to Infection.Immunity, inflammation and disease · 2024Article
- Serotype distribution and antimicrobial resistance ofNew microbes and new infections · 2024Article
- Fourier transform infrared spectroscopy forFrontiers in microbiology · 2024Article
- Pneumococcal Vaccine Breakthrough and Failure in Infants and Children: A Narrative Review.Vaccines · 2023Review
- Changes in Invasive Pneumococcal Disease in the Paediatric Population in the Second COVID-19 Pandemic Year.Vaccines · 2023Article
- Emerging vaccine strategies against the incessant pneumococcal disease.NPJ vaccines · 2023Review
- Magnetic bead-based separation of pneumococcal serotypes.Cell reports methods · 2023Article
- Enhancing efficacy of existing antibacterials against selected multiple drug resistant bacteria using cinnamic acid-coated magnetic iron oxide and mesoporous silica nanoparticles.Pathogens and global health · 2022Article
- Continued Vaccine Breakthrough Cases of Serotype 3 Complicated Pneumonia in Vaccinated Children, Portugal (2016-2019).Microbiology spectrum · 2022Article
- Serotypes and Clonal Composition of Streptococcus pneumoniae Isolates Causing IPD in Children and Adults in Catalonia before 2013 to 2015 and after 2017 to 2019 Systematic Introduction of PCV13.Microbiology spectrum · 2021Article
- Pediatric Invasive Pneumococcal Disease Three Years after PCV13 Introduction in the National Immunization Plan-The Continued Importance of Serotype 3.Microorganisms · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite use of 7-valent pneumococcal conjugate vaccine, incidence of pleural effusion and empyema (pediatric complicated pneumococcal pneumonia [PCPP]) is reportedly increasing globally. We cultured and performed PCR on 152 pleural fluid samples recovered from pediatric patients in Portugal during 2010-2015 to identify and serotype Streptococcus pneumoniae. We identified only 17 cases by culture, but molecular methods identified S. pneumoniae in 68% (92/135) of culture-negative samples. The most frequent serotypes were 3, 1, and 19A, together accounting for 62% (68/109) of cases. Nineteen cases attributable to 13-valent pneumococcal conjugate vaccine (PCV13) serotypes (mostly serotype 3) were detected among 22 children age-appropriately vaccinated with PCV13. The dominance of the additional serotypes included in PCV13 among PCPP cases in Portugal continues, even with PCV13 available on the private market (without reimbursement) since 2010 and with average annual coverage of 61% among age-eligible children. Our data suggest reduced effectiveness of PCV13 against serotype 3 PCPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.